Business Wire

• ‘Ultra-sensitive’ cancer blood test is highly accurate in identifying which breast cancer patients will relapse
• The ‘Personalis NeXT Personal® liquid biopsy’ test uses whole genome sequencing to identify up to 1,800 mutations in a patient’s tumour DNA that can identify recurrence of the patient’s cancer from a blood sample
• The median lead time from detection of disease to clinical relapse (shown on imaging) was 15 months – over three months... (continue reading...)

​​​First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal... (continue reading...)

• The results include data from three main study cohorts: In the non-squamous non-small cell lung cancer (NSCLC) cohort, an Objective Response Rate (ORR) for NSCLC of 19.0% (4/21), with 2 Partial Responses (PR) and 2 Complete Responses (CR) was observed. In the UC cohort, the ORR was 19.2% (5/26), with 4 PRs and 1 CR. In HCC, data from the first 20 patients showed an ORR of 20.0% (4/20), with 3 PRs and 1 CR in the early readouts.
• Exceptional Duration of Response... (continue reading...)

• DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS)
• Median PFS not yet reached at 21.8 months median follow-up versus 12.7 months in bortezomib combination
• Second trial to show robust efficacy for a belantamab mafodotin combination versus a standard of care in second line and later relapsed/refractory multiple myeloma
• Results simultaneously published in the New... (continue reading...)

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, human epidermal growth factor receptor 2-negative (HER2-negative), hormone receptor-positive metastatic breast cancer (TBCRC 041; ... (continue reading...)